Articles

Medical Psilocybin and the Emerging “Functional” Mushrooms Market

Medical Psilocybin and the Emerging “Functional” Mushrooms Market

Investing News Network highlights the investment opportunity in the psychedelic-assisted therapy space and considers Numinus's unique position. Click here to read the full article.

Numinus licensed by Health Canada to extract and research psilocybin

Numinus licensed by Health Canada to extract and research psilocybin

Numinus CEO Payton Nyquvest and Chief Operating Officer Michael Tan spoke to Mugglehead about an amendment to the company's Health Canada licence which will allow them to produce and extract…

Numinus Licencing Amendment: We Speak to the Team

Numinus Licencing Amendment: We Speak to the Team

Numinus Chief Operating Officer Michael Tan explains what the company's recent Health Canada licence amendment, which will allow them to produce and extract psilocybin from mushrooms, means for…

Psychedelics Stocks to Watch

Psychedelics Stocks to Watch

Investing News Network highlights Numinus' unique value proposition in this article. Click here to read the full article.

We can no longer ignore the potential of psychedelic drugs to treat depression

We can no longer ignore the potential of psychedelic drugs to treat depression

Dr. Robin Carhart-Harris, Head of the Centre for Psychedelic Research at Imperial College London, writes of the Centre's work comparing psilocybin to conventional antidepressants and the potential of…

Growing body of research shows patients with addiction, PTSD, and depression can benefit from psychedelic substances

Growing body of research shows patients with addiction, PTSD, and depression can benefit from psychedelic substances

In a discussion with CannCentral, Numinus Wellness Chief Medical Officer Dr. Evan Wood cautions that psychedelic assisted psychotherapy is not a cure for everybody—but trials have shown statistically…

A Big Week For Psychedelics Co. Numinus Wellness

A Big Week For Psychedelics Co. Numinus Wellness

Benzinga highlights a busy week for Numinus, in which the company listed on the TSX Venture Exchange and appointed a new Chief Medical Officer, Dr. Evan Wood. Click here to read the full article.

B.C. MP calls for legalization of some psychedelic drugs

B.C. MP calls for legalization of some psychedelic drugs

CityNews TV talks to Numinus CEO Payton Nyquvest and advisor Gabor Mate about the future of psychedelic drugs as a potential treatment for mental health issues and addiction. Click here to watch the…

Canada could regulate psychedelic therapy within few years, bets company

Canada could regulate psychedelic therapy within few years, bets company

Numinus Wellness outlines where they see the business and the industry going following their public listing and announcement of Dr. Evan Wood as Chief Medical Officer. Click here to read the full…

Interview with Dr. Evan Wood, CMO at Numinus

Interview with Dr. Evan Wood, CMO at Numinus

In an interview with Psilocybin Alpha, Numinus Chief Medical Officer Dr. Evan Wood outlines his thoughts on the future of psychedelics and society and where he sees Numinus’ role. Click here to read…

Vancouver-based Numinus Wellness hires addiction expert Dr. Evan Wood as chief medical officer

Vancouver-based Numinus Wellness hires addiction expert Dr. Evan Wood as chief medical officer

Numinus Chief Medical Officer Dr. Evan Wood needs no introduction to anyone who’s followed the harm-reduction movement in British Columbia over the past two decades. CannCentral details Dr. Wood’s…

Psychedelic Pioneer Rick Doblin On FDA Trials Of MDMA: Most Important Reality Check Of MAPS’ 34-Year History

Psychedelic Pioneer Rick Doblin On FDA Trials Of MDMA: Most Important Reality Check Of MAPS’ 34-Year History

Forbes talks with MAPS Founder Rick Doblin on the latest advances in research into the safety and efficacy of the use of MDMA-assisted psychotherapy to treat PTSD. Click here to read the full article.